Role of Nonpharmacologic Approach to Fracture and Osteoporosis

  • Richard L. Prince


In view of the extremely high rates of osteoporotic fracture occurring in aB developed and many developing countries, a population-based nonpharmacologic approach to the treatment and prevention of facture and osteoporosis has many attractions. The major reason for the increasing importance of a public health approach to osteoporotic fracture is the increasing longevity of both men and women. Average life expectancy in most developed countries is about 85 years for women and 78 years for men. The incidence rates for all fractures show a peak in adolescence and a rising age-specific incidence from approximately 50 years on in both men and women. Thus, nonpharmacologic public health prevention efforts should be directed to individuals at these two specific times of life.


Bone Loss Bone Density Anorexia Nervosa Calcium Supplementation Dietary Calcium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Watts NB: Bisphosphonate treatment for osteoporosis. In The Osteoporotic Syndrome. Edited by Avioli LV. San Diego: Academic Press, 2000:121–132.CrossRefGoogle Scholar
  2. 2.
    Rogers MJ, Gordon S, Benford HL, et al.: Cellular and molecular mechanisms of action of bisphosphonates [review]. Cancer 2000, 88 (12 suppl):2961–2978.PubMedCrossRefGoogle Scholar
  3. 3.
    Tucci JR, Tonino RP, Emkey RD, et al.: Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996, 101:488–501.PubMedCrossRefGoogle Scholar
  4. 4.
    Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis—a randomized controlled trial. JAMA 1999, 282:1344–1352.PubMedCrossRefGoogle Scholar
  5. 5.
    Hosking D, Chilvers CED, Christiansen C, et al.: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age: Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998, 338:485–492.PubMedCrossRefGoogle Scholar
  6. 6.
    Orwoll E, Ettinger M, Weiss S, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604–610.PubMedCrossRefGoogle Scholar
  7. 7.
    Reid DM, Hughes R, Laan RF, et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000, 15:1006–1013.PubMedCrossRefGoogle Scholar
  8. 8.
    Black DM, Cummings SR, Karpf DB, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535–1541.PubMedCrossRefGoogle Scholar
  9. 9.
    Wallach S, Cohen S, Reid DM, et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000, 67:277–285.PubMedCrossRefGoogle Scholar
  10. 10.
    Tonino RP, Meunier PJ, Emkey R, et al.: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000, 85:3109–3115.PubMedCrossRefGoogle Scholar
  11. 11.
    Schnitzer TJ, Bone HG, Crepaldi G, et al.: Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily for treatment of postmenopausal osteoporosis. Aging Clin Exp Res 2000, 12:1–12.Google Scholar
  12. 12.
    Brown JP, Kendler DL, McClung MR, et al.: The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103–111.PubMedCrossRefGoogle Scholar
  13. 13.
    Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653–661.PubMedCrossRefGoogle Scholar
  14. 14.
    Bone HG, Greenspan SL, McKeever C, et al.: Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000, 85:720–726.PubMedCrossRefGoogle Scholar
  15. 15.
    Compston JE, Watts NB: Combination therapy for postmenopausal osteoporosis. Clin Endocrinol 2002, 56:565–569.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Richard L. Prince

There are no affiliations available

Personalised recommendations